Work

Supplemental Figures from Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Figure 1 Species-specific activation of TLR8 by motolimod. Supplemental Figure 2 Full human immune cell reconstitution in NSG-HIS mice. Supplemental Figure 3 Response to PLD + motolimod is not schedule-sensitive in the NSG-HIS mouse. Supplemental Figure 4 Assessment of macrophage-induced apoptosis using motolimod in combination with PLD. Supplemental Figure 5 Isolation of tumor-infiltrating T cells with specific tumor recognition and lysis ex vivo. Supplemental Figure 6 Pharmacokinetic (PK) evaluations. Supplemental Figure 7 Biological efficacy of motolimod in combination with paclitaxel.

DOI: 10.1158/1078-0432.22465806.v1

Authors: Bradley J. Monk, Andrea Facciabene, William E. Brady, Carol A. Aghajanian, Paula M. Fracasso, Joan L. Walker, Heather A. Lankes, Kristi L. Manjarrez, Gwenn-äel H. Danet-Desnoyers, Katherine M. Bell-McGuinn, Carolyn K. McCourt, Alexander Malykhin, Robert M. Hershberg, George Coukos

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361818090

Cites:

Cited by:

Related to: 10